Skip to main content
. 2022 Nov 18;23(1):142. doi: 10.1186/s10194-022-01515-8

Table 4.

Adverse and serious adverse events up to 6 months of observation

Most reported adverse events (AEs) n (%) N = 99
Constipation 21 (21.2)
Insufficient effect 6 (6.1)
Lack of efficacy 6 (6.1)
Diarrhea 5 (5.1)
Injection site reaction 2 (2.0)
Serious adverse events (SAEs) n (%) 12 (12.1)
 Anaphylactic shocka 1 (1.0)
 Chest pain and arm pain left side 1 (1.0)
 COVID-19 1 (1.0)
 Inpatient headache therapy 2 (2.0)
 Kidney stone 1 (1.0)
 Medication overuse headache needing withdrawal in hospital setting 1 (1.0)
 Meningioma 1 (1.0)
 Mycoplasma pneumonia 1 (1.0)
 Right motor and sensory syndrome and migraine 1 (1.0)
 Transitory ischemic attack 1 (1.0)
 Urinary tract infection 1 (1.0)

aFour months after erenumab discontinuation, hence no causal relationship assumed

Abbreviations: AE Adverse event, SAE Serious adverse event